Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

CARDIAC BIOMARKERS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Million. The market is analyzed by Location-wise (Clinical Laboratory Testing, and Point-of-Care Testing) and by Assay types (Acute Myocardial Infarction (AMI) Tests (Creatine Kinase-MB (CK-MB), Cardiac Troponin, & Myoglobin), and Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)). The report provides separate omprehensive analytics for the US, Europe, and Rest of the World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 58 companies including many key and niche players such as Abbott Diagnostics, Alere, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., BG Medicine, biomérieux, LifeSign LLC, Nanogen Inc., Ortho-Clinical Diagnostics, Inc., Prognostix, Inc., Response Biomedical Corp., Roche Diagnostics Corp., and Siemens Healthcare Diagnostics, Inc..Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1632
Price : $4500
Companies : 58
Pages : 444
Date : October 2011
Market Data Tables : 115
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  CARDIAC BIOMARKERS (Complete Report) Pages : 444   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.....I-13 $295  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
  2. INDUSTRY OVERVIEW.....II-413 $1950  
   Cardiovascular Diseases: Leading cause of Mortality Worldwide.....II-4
Table 1: A Review of Region-Wise Incidence and Prevalence of Cardiovascular Diseases: 2006.....II-4
1$350
   Basic Topologies of Cardiovascular Diseases.....II-5 1$100
   Table 2: Leading Causes of Death in Low Income Nations (includes corresponding Graph/Chart).....II-61$350
   Table 3: Leading Causes of Death in Middle Income Nations (includes corresponding Graph/Chart).....II-71$350
   Table 4: Leading Causes of Death in High Income Nations (includes corresponding Graph/Chart).....II-8
Cardiac Biomarkers: A Snapshot.....II-8
1$350
   Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs.....II-9
Cardiac Biomarkers - Making Diagnosis Easier and Quicker.....II-9
What is a Cardiac BioMarker.....II-9
1$100
   Necessity of a Cardiac Marker Assay Test.....II-10
How it works?.....II-10
1$100
   Major Cardiac Markers and their Properties.....II-11
Market Analysis.....II-11
1$100
   Market Trends.....II-12
Strong Demand for Risk Assessment Markers.....II-12
Intense Competition among Players in the Cardiac Diagnostics Market.....II-12
Siemens Healthcare: World’s Largest Fully Integrated Diagnostics Company.....II-12
1$100
   Product Portfolio of Bayer and Dade Behring.....II-131$100
   The Future of Cardiac Marker POCT Segment.....II-14
Need for Early Detection Markers.....II-14
1$100
   Rapid Turnaround time: A Crucial Parameter for POC Testing Kits.....II-15
Stroke Biomarkers: A Review.....II-15
Player Initiatives in the Recent Years.....II-15
2$200
  3. TRENDS IN RESEARCH AND DEVELOPMENT.....II-174 $295  
   Increasing Health Burden Drives Research Efforts.....II-17
High-Performance Techniques Drive Biomarker Discovery in Cardiology.....II-17
Effective Phenotyping Takes Precedence for Successful Genotyping Studies.....II-17
1$100
   Biomarkers of ACS: A Leading Segment.....II-18
Biomarkers – A Promising Diagnostic Tool for ACS.....II-18
1$100
   New Diagnostic Biomarkers for ACS on the Anvil.....II-19
Biomarker Discovery in Cardiovascular Diseases to Undergo Significant Changes.....II-19
1$100
   Genomic Biomarkers for Detecting Cardiovascular Diseases.....II-20
Growing Demand for Stroke Biomarkers.....II-20
Rising Incidence of the Disease – A Major Driver for Stroke Biomarkers.....II-20
1$100
  4. CARDIAC MARKERS AND MYOCARDIAL INFARCTION.....II-217 $495  
   Chain Reaction after an Event of MI.....II-21
Action Plan after an Event of MI.....II-21
1$100
   Protocol for Conducting AMI Markers Tests.....II-22
Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations.....II-22
Creatine Kinase – The Traditional Gold Standard, Loosing Sheen.....II-22
1$100
   Market and Forecasts:.....II-23
Isomers.....II-23
Kinetics.....II-23
Purpose of Test and When to Order.....II-23
Evaluation.....II-23
Points to remember.....II-23
1$100
   Cardiac Troponin – Taking Over from CK-MB.....II-24
Market and Forecast.....II-24
Overview.....II-24
Troponin Tissue-Specific Subtypes.....II-24
1$100
   Other Diseases.....II-25
Uses of Troponin Tests.....II-25
New Advanced High-sensitivity (Hs) Cardiac Troponin Tests.....II-25
1$100
   Myoglobin.....II-26
Purpose of Test and When to Order.....II-26
Testing and Evaluation.....II-26
Points to Remember.....II-26
1$100
   Market and Forecast.....II-271$100
  5. CARDIAC MARKERS AND CONGESTIVE HEART FAILURE (CHF).....II-285 $395  
   Key Facts.....II-28
BNP (B-type Natriuretic Peptide).....II-28
1$100
   NT-proBNP (N-terminal proBNP).....II-29
Purpose of Tests and When to Order.....II-29
Testing and Evaluation.....II-29
1$100
   Points to Remember.....II-30
Market and Forecast.....II-30
Introduction of BNP Test and the Changing Market Scenario in the Segment: A
  Review.....II-30
1$100
   Player Strategies in the BNP and NT-proBNP Testing Market: A Review.....II-31
Choosing the Right BNP and NT proBNP Assay Kit in the Market.....II-31
Evolution of BNP and NT proBNP Market.....II-31
1$100
   NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with
  Reduced Kidney Function.....II-32
1$100
  6. OTHER IMPORTANT CARDIAC BIOMARKERS.....II-335 $395  
   Homocysteine.....II-33
C-Reactive Protein.....II-33
1$100
   Plasminogen Activator Inhibitor-1.....II-34
D-Dimer.....II-34
Thrombus Precursor Protein.....II-34
Galectin-3 Biomarker.....II-34
1$100
   Galectin-3: An Overview of Clinical Studies.....II-35
Galectin-3: Overview of Clinical Studies in Cardiovascular Disease Diagnosis.....II-35
Potential Future Cardiac Biomarkers.....II-35
3$300
  7. CARDIAC BIOMARKER TESTING IN CLINICAL LABORATORIES.....II-38   
   Market and Forecast.....II-381$100
  8. CARDIAC BIOMARKERS AT POINT-OF- CARE TESTING.....II-39   
   Market and Forecast.....II-391$100
   Major Players Operating in the Cardiac Markers POCT Segment.....II-40
Cardiac Markers Point-of-Care testing (POCT) Segment: Major Players & Their Operating
  Brands......II-40
1$100
  9. STRATEGIC CORPORATE DEVELOPMENTS.....II-4115 $950  
   BG Medicine and Boston Scientific Partner for Collaborative Research.....II-41
HDL and Gamma Therapeutics to Offer Biomarker Assay Tests for Risk Assessment of Stroke
  and Heart attack.....II-41
Pacific Biomarkers Enters into Research Deals with Two Multinational Firms.....II-41
1$100
   Roche Enters into Cross-Licensing Agreement with Alere.....II-42
ACC and Roche Diagnostics Initiate Collaboration.....II-42
Aushon BioSystems Enters into Partnership with LightArray Biotech.....II-42
1$100
   Inverness Medical Innovations Changes Name to Alere.....II-43
BG Medicine Inks Agreement with LabCorp.....II-43
Siemens and Eko Diagnostics to Establish a PET Biomarkers Manufacturing.....II-43
Caprion Takes over PPD’s Biomarker Business.....II-43
Corgenix Medical Inks Supply Agreement with BG Medicine.....II-43
1$100
   ELITech Buys Out Nanogen Assets.....II-44
Cordex and BG Medicine to join Forces for Clinical Investigation of Biomarkers for
  Cardiac Failure.....II-44
Asbach and Oxford Biosystems Ink Distribution Agreements with Athera.....II-44
1$100
   GCIC Grants Funds to Prognostix to Further Product Development.....II-45
Thermo Fisher Scientific Takes over B.R.A.H.M.S.....II-45
Response Biomedical Signs Partnership Agreement with Roche.....II-45
1$100
   Compugen Announces Discovery of Troponin I Biomarker Variant, Inks Agreement with
  Biosite.....II-46
Inverness Acquires Biosite.....II-46
Siemens Acquires Diagnostic Division of Bayer Healthcare.....II-46
Siemens Announces Acquisition of Dade Behring.....II-46
1$100
   Beckman Collaborates in CVD Related Research Projects.....II-47
Dade Behring Receives Sublicense to New Cardiac Marker.....II-47
Inverness Acquires Cholestech.....II-47
1$100
   Response Biomedical Secures Clearance to Market RAMP® NT-proBNP Test.....II-48
Acrongenomics Collaborates with Molecular Vision and Pearson Matthews.....II-48
BG Medicine Obtains Rights to Develop Tests for Congestive Heart Failure.....II-48
Nanogen Gains US Reissue Patent for Combined Use of Biomarkers for CHF
  Diagnosis.....II-48
1$100
   Nanogen Secures FDA Approval for CHF NT-proBNP EDTA Plasma Test.....II-49
Roche Diagnostics Secures FDA Approval for Roche Elecsys® proBNP Test.....II-49
Nanogen Acquires Rapid Cardiac Immunoassay Test Businesses of SDI.....II-49
1$100
   Response Biomedical Starts Clinical Trials of the RAMP NT- proBNP Test.....II-50
Procter and Gamble, Inverness to Form JV for Consumer Diagnostics.....II-50
Roche Diagnostics Grants Rights for NT- proBNP to Mitsubishi Kagaku Latron.....II-50
Bayer Healthcare Receives FDA Approval for Troponin-I-Test Tnl-Ultra.....II-50
1$100
   MKI Obtains EU Approval and CE Mark for Four Cardiac Markers.....II-51
Dade Behring Grants PIGF Rights to Abbott.....II-51
Siemens and PETNET Pharmaceuticals Acquire PETNET’s New England Operations.....II-51
OXIS International Acquires Biocheck.....II-51
1$100
   Wampole, Roche collaborate on Ischemia Modified Albumin Test.....II-52
Nanogen Extends Point-of-Care Diagnostic Tests Distribution in Europe.....II-52
Abbott, Cleveland Clinic Agrees to Develop MPO Cardiac Test.....II-52
Roche Diagnostics Grants Rights to Response Biomedical for Troponin T and NT-
  proBNP.....II-52
1$100
   Inverness Acquires Ischemia Technologies.....II-53
Roche Diagnostics Grants Rights for NT- proBNP to bioMerieux.....II-53
1$100
   Roche Confers Rights of NT-proBNP to Ortho-Clinical Diagnostics.....II-54
Dade Behring Grants CRP Sublicense to Roche Diagnostics.....II-54
Roche Awards Non Exclusive Rights of NT-proBNP marker to DPC.....II-54
Abbott Gains Approval for CK-MB Test in the US.....II-54
1$100
   i-STAT Gains Approval for Troponin I Test from US FDA.....II-551$100
  10. PRODUCT LAUNCHES/DEVELOPMENTS/ APPROVALS.....II-5610 $595  
   Eisai and Sanko to Unveil Cobas h 232 Series.....II-56
bioMerieux and Philips Co-Develop an Advanced Rapid POCT Solution for Emergency
  Testing.....II-56
Singulex Secures US patent for use of Erenna Technology in Diagnosing Low Troponin-I
  Levels.....II-56
1$100
   BG Medicine Receives FDA Clearance for Galactin-3 Assay.....II-57
Roche Launches STAT Immunoassays Module.....II-57
Alere International Launches New Triage® NT-proBNP Test.....II-57
1$100
   Abbott Laboratories and BG Medicine Ink Agreement.....II-58
PGxHealth Unveils Familion DCM Genetic Test.....II-58
Roche Diagnostics Launches Cardiac 200.....II-58
Thermo Fisher Scientific Introduces Biomarker based Diagnostics for Heart Attack in
  Europe.....II-58
1$100
   Alere Introduces Triage® NT-proBNP Test.....II-59
Celera Inks Non-Exclusive License Agreement with Perlegen Sciences.....II-59
Maine Standards Launches VALIDATE CM2 Test Set.....II-59
1$100
   Response Bags FDA Clearance for RAMP® NT-proBNP Test.....II-60
bioMérieux Rolls out VIDAS® NT-proBNP.....II-60
Roche Diagnostics Introduces Cobas-H-232 Handheld Cardiac Marker System.....II-60
OXIS Discovers a Unique Diagnostic Biomarker for Cardiovascular Disease.....II-60
1$100
   Ortho-Clinical Presents Sensitivity Troponin I Test, VITROS Troponin I ES.....II-61
bioMerieux Unveils ‘VIDAS® Troponin I Ultra’.....II-61
Roche Elecsys proBNP Assay Secures FDA Clearance.....II-61
1$100
   Bayer Launches New Tnl-Ultra™ Troponin Assay on ADVIA Centaur® CP Immunoassay
  system.....II-62
Ortho-Clinical Diagnostics Receives FDA Clearance for VITROS NT-proBNP Assay.....II-62
1$100
   Dade Behring Launches CardioPhase® hsCRP Test.....II-63
Diagnostic Products Corporation to Market NT-proBNP Outside US.....II-63
Dade Behring Introduces Homocysteine Assay for BN™ System.....II-63
Biosite Develops Triage® Cardio ProfilER™ Panel.....II-63
1$100
   A Breakthrough Biochip Array System for MI.....II-64
FDA Approves Emergency Department Diagnostic Test from Biosite.....II-64
Response Biomedical Obtains Regulatory Clearance for RAMP®.....II-64
Response Biomedical Gains US FDA Approval for 3rd RAMP® Test.....II-64
1$100
   CLINIQA Rolls Out Liquid Stable Cardiac Marker Controls.....II-65
Abbott Releases AxSYM® Troponin-I ADV Assay in World Markets.....II-65
1$100
  11. FOCUS ON SELECT GLOBAL PLAYERS.....II-665 $395  
   Abbott Diagnostics (USA).....II-66
Alere, Inc. (USA).....II-66
Ani Biotech Oy (Finland).....II-66
1$100
   Axis-Shield PoC (UK).....II-67
Beckman Coulter, Inc. (USA).....II-67
BG Medicine (USA).....II-67
1$100
   biomérieux (France).....II-68
LifeSign LLC (USA).....II-68
1$100
   Ortho-Clinical Diagnostics, Inc. (USA).....II-69
Prognostix, Inc. (USA).....II-69
Response Biomedical Corp. (Canada).....II-69
1$100
   Roche Diagnostics Corp. (USA).....II-70
Siemens Healthcare Diagnostics, Inc. (USA).....II-70
1$100
  12. GLOBAL MARKET PERSPECTIVE.....II-71   
   Table 5: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-711$350
   Table 6: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-721$350
   Table 7: World 15-Year Perspective for Cardiac Biomarkers by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart).....II-731$350
   Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-741$350
   Table 9: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-751$350
   Table 10: World 15-Year Perspective for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart).....II-761$350
   Table 11: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-771$350
   Table 12: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-781$350
   Table 13: World 15-Year Perspective for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart).....II-791$350
   Table 14: World Recent Past, Current & Future Analysis for CK-MB Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2017 (includes corresponding Graph/Chart).....II-801$350
   Table 15: World Historic Review Analysis for CK-MB Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-811$350
   Table 16: World 15-Year Perspective for CK-MB Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart).....II-821$350
   Table 17: World Recent Past, Current & Future Analysis for Cardiac Troponin Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-831$350
   Table 18: World Historic Review Analysis for Cardiac Troponin Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-841$350
   Table 19: World 15-Year Perspective for Cardiac Troponin Assay Test by Geographic Region – USA, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2017 (includes corresponding Graph/Chart).....II-851$350
   Table 20: World Recent Past, Current & Future Analysis for Myoglobin Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-861$350
   Table 21: World Historic Review Analysis for Myoglobin Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-871$350
   Table 22: World 15-Year Perspective for Myoglobin Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart).....II-881$350
   Table 23: World Recent Past, Current & Future Analysis for BNP & NT-proBNP Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-891$350
   Table 24: World Historic Review Analysis for BNP & NT-proBNP Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-901$350
   Table 25: World 15-Year Perspective for BNP & NT- proBNP Assay Test by Geographic Region – US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart).....II-911$350
  13. THE UNITED STATES.....II-9233 $4200  
   A. Market Analysis.....II-92
Cardiovascular Diseases in the US: A Review.....II-92
Heart Facts.....II-92
1$100
   Table 26: The US Disease Statistics for Coronary Heart Disease (CHD) & Myocardial Infarction (MI).....II-93

Table 27: Prevalence of Cardiovascular Diseases in the US by Type (2007-2009) (includes corresponding Graph/Chart).....II-93
1$350
   Table 28: The US Prevalence of Coronary Heart Disease (CHD) as a Percentage of Total Population by Age-group & Sex, in 2005 - 06. (includes corresponding Graph/Chart).....II-94

Table 29: The US Annual Number of New & Recurrent Adults diagnosed with Heart Attack by Age & Sex in the Recent Past (includes corresponding Graph/Chart).....II-94
1$350
   Table 30: The US Disease Statistics for Heart Failure.....II-95

Table 31: The Annual Number of Americans Diagnosed with Heart Failure as 'per 1000 persons' by Age & Sex, in the Recent Past (includes corresponding Graph/Chart).....II-95
Number of Deaths due to Heart Diseases & Strokes: A Historic Review.....II-95
1$350
   Senior Citizens at High Risk for Heart Failure.....II-96
CHF Biomarkers to Spearhead the US market.....II-96
US Cardiac Markers POCT Segment.....II-96
1$100
   Table 32: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue held by Major Players (Siemens, Beckman Coulter, and Others) in 2010(E) (includes corresponding Graph/Chart).....II-97

Table 33: US CHF (Congestive Heart Failure) Diagnostics Market: Market Share by Revenue held by Major Players (Siemens, Alere, Beckman Coulter, and Others) in 2010(E) (includes corresponding Graph/Chart).....II-97
1$350
   Product Launches/Approvals/Developments.....II-985$500
   Strategic Corporate Developments.....II-10312$850
   Focus on Select Key Players.....II-115
Abbott Diagnostics.....II-115
Beckman Coulter, Inc......II-115
BG Medicine (USA).....II-115
1$100
   diaDexus, Inc......II-116
Inverness Medical Innovations, Inc......II-116
1$100
   LifeSign LLC.....II-117
Ortho-Clinical Diagnostics, Inc......II-117
Prognostix, Inc......II-117
Roche Diagnostics Corp......II-117
1$100
   Siemens Healthcare Diagnostics, Inc......II-1181$100
   B. Market Analytics.....II-119
Table 34: The US Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-119
1$350
   Table 35: The US Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1201$350
   Table 36: The US 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1211$350
   Table 37: The US Recent Past, Current and Future Analysis for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1221$350
   Table 38: The US Historic Review Analysis for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1231$350
   Table 39: The US 15-Year Perspective for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1241$350
  14. EUROPE.....II-12512 $2950  
   A. Market Analysis.....II-125
European Cardiovascular Diseases Fact Sheet.....II-125
Evolution of the European Cardiac Risk Markers Market.....II-125
1$100
   Cardiac Markers in Primary Care Sector.....II-126
Product Launches/Approvals/Developments.....II-126
1$100
   Strategic Corporate Developments.....II-1271$100
   B. Market Analytics.....II-128
Table 40: European Recent Past, Current and Future Analysis for Cardiac Markers by Region – France, Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-128
1$350
   Table 41: European Historic Review Analysis for Cardiac Markers by Region – France, Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1291$350
   Table 42: European 15-Year Perspective for Cardiac Markers by Region – France, Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1301$350
   Table 43: European Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1311$350
   Table 44: European Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1321$350
   Table 45: European 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017.....II-1331$350
   Table 46: European Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1341$350
   Table 47: European Historic Review Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1351$350
   Table 48: European 15-Year Perspective for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1361$350
  14a. FRANCE.....II-1375 $950  
   A. Market Analysis.....II-137
Product Launches/Approvals/Developments.....II-137
1$100
   Strategic Corporate Developments.....II-138
BioMérieux – A Key Player.....II-138
1$100
   B. Market Analytics.....II-139
Table 49: French Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-139
1$350
   Table 50: French Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1401$350
   Table 51: French 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1411$350
  14b. GERMANY.....II-1424 $950  
   A. Market Analysis.....II-142
Rennesens GmbH.....II-142
Strategic Corporate development.....II-142
1$100
   B. Market Analytics.....II-143
Table 52: German Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-143
1$350
   Table 53: German Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1441$350
   Table 54: German 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1451$350
  14c. ITALY.....II-1463 $950  
   Market Analysis.....II-146
Table 55: Italian Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-146
1$350
   Table 56: Italian Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1471$350
   Table 57: Italian 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1481$350
  14d. THE UNITED KINGDOM.....II-1496 $1450  
   A. Market Analysis.....II-149
UK Cardiovascular Diseases Fact Sheet.....II-149
1$100
   Table 58: The UK’s Healthcare Costs of Cardio Vascular Diseases (CVD), Coronary Heart Diseases (CHD) & Strokes in 2006 (includes corresponding Graph/Chart).....II-150
Strategic Corporate Development.....II-150
1$350
   Product Launch.....II-151
Axis-Shield PoC: A Key Player.....II-151
1$100
   B. Market Analytics.....II-152
Table 59: The UK Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-152
1$350
   Table 60: The UK Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1531$350
   Table 61: The UK 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1541$350
  14e. REST OF EUROPE.....II-1554 $950  
   A. Market Analysis.....II-155
Ani Biotech Oy: A Key Player.....II-155
1$100
   B. Market Analytics.....II-156
Table 62: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-156
1$350
   Table 63: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-1571$350
   Table 64: Rest of Europe 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1581$350
  15. REST OF WORLD.....II-15913 $2450  
   A. Market Analysis.....II-159
Evolution of BNP Test market in Japan.....II-159
Canada: cardiovascular disease facts.....II-159
1$100
   Table 65: Heart Disease in Canada by Province: an Overview (includes corresponding Graph/Chart).....II-160
Heart Attacks.....II-160
Cardiac Arrest.....II-160
Heart Failure.....II-160
1$350
   Stroke.....II-161
Congenital Heart Disease.....II-161
Product Launches/Approvals/Developments.....II-161
2$200
   Strategic Corporate Developments.....II-1632$200
   Focus on Select Key Players.....II-165
Response Biomedical Corporation.....II-165
Sekisui Medical Co. Ltd......II-165
Shionogi and Co. Ltd......II-165
1$100
   B. Market Analytics.....II-166
Table 66: Rest of the World Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2017 (includes corresponding Graph/Chart).....II-166
1$350
   Table 67: Rest of the World Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1671$350
   Table 68: Rest of the World 15-Year Perspective for Cardiac Markers by Segment – Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1681$350
   Table 69: Rest of the World Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1691$350
   Table 70: Rest of the World Historic Review Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1701$350
   Table 71: Rest of the World 15-Year Perspective for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-1711$350
COMPETITION 258$995
  
Total Companies Profiled: 58 (including Divisions/Subsidiaries - 75)

Region/Country                 Players


The United States                 32   
Canada                             4
Japan                              3
Europe                            20 
     France                        3
     Germany                       1
     The United Kingdom            6
     Spain                         1
     Rest of Europe                9
Asia-Pacific (Excluding Japan)    13 
Latin America                      1
Middle-East                        2
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign